247 related articles for article (PubMed ID: 26684001)
21. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
[TBL] [Abstract][Full Text] [Related]
22. Validation of Independent Prognostic Value of Asphericity of
Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
[TBL] [Abstract][Full Text] [Related]
23. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
26. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.
Jeong E; Hyun SH; Moon SH; Cho YS; Kim BT; Lee KH
Medicine (Baltimore); 2017 Feb; 96(5):e5935. PubMed ID: 28151879
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.
Billè A; Okiror L; Skanjeti A; Errico L; Arena V; Penna D; Ardissone F; Pelosi E
Clin Lung Cancer; 2013 Mar; 14(2):149-56. PubMed ID: 22682667
[TBL] [Abstract][Full Text] [Related]
28. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
30. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
32. Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.
Hyun SH; Ahn HK; Lee JH; Choi JY; Kim BT; Park YH; Im YH; Lee JE; Nam SJ; Lee KH
PLoS One; 2016; 11(10):e0165814. PubMed ID: 27798667
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
Zhang H; Wroblewski K; Pu Y
Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
[TBL] [Abstract][Full Text] [Related]
34. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
[TBL] [Abstract][Full Text] [Related]
35. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
Nair VS; Barnett PG; Ananth L; Gould MK;
Chest; 2010 May; 137(5):1150-6. PubMed ID: 20038738
[TBL] [Abstract][Full Text] [Related]
36. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
[TBL] [Abstract][Full Text] [Related]
37. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
[TBL] [Abstract][Full Text] [Related]
39. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.
Konings R; van Gool MH; Bard MP; Zwijnenburg A; Titulaer BM; Aukema TS; Valdés Olmos RA; Sikorska K; Klomp HM; Rijna H
Ann Nucl Med; 2016 Jun; 30(5):362-8. PubMed ID: 26961089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
